Prudential Financial Inc. Has $77.11 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Prudential Financial Inc. boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 261.3% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 955,539 shares of the medical equipment provider’s stock after buying an additional 691,052 shares during the period. Prudential Financial Inc.’s holdings in Hologic were worth $77,112,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of HOLX. GPS Wealth Strategies Group LLC acquired a new position in Hologic during the first quarter worth $28,000. Sageworth Trust Co acquired a new position in Hologic during the first quarter worth $34,000. Salem Investment Counselors Inc. grew its position in shares of Hologic by 163.9% in the second quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 341 shares during the last quarter. Whittier Trust Co. grew its position in shares of Hologic by 55.5% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 211 shares during the last quarter. Finally, Compagnie Lombard Odier SCmA acquired a new stake in shares of Hologic in the fourth quarter valued at about $55,000. 92.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

HOLX has been the topic of several research analyst reports. TheStreet downgraded Hologic from a “b” rating to a “c+” rating in a research report on Monday, July 31st. Royal Bank of Canada lowered their price target on Hologic from $87.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Tuesday, August 1st. Citigroup lowered their price target on Hologic from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 1st. Raymond James lowered their price target on Hologic from $100.00 to $95.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 1st. Finally, StockNews.com assumed coverage on shares of Hologic in a research note on Friday, August 18th. They issued a “buy” rating for the company. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $88.92.

Hologic Stock Down 1.4 %

NASDAQ HOLX opened at $74.06 on Wednesday. The company has a current ratio of 4.42, a quick ratio of 3.73 and a debt-to-equity ratio of 0.54. The stock’s 50 day moving average is $77.58 and its two-hundred day moving average is $79.82. The company has a market capitalization of $18.14 billion, a price-to-earnings ratio of 38.37 and a beta of 1.01. Hologic, Inc. has a 1-year low of $59.78 and a 1-year high of $87.88.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, July 31st. The medical equipment provider reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.04. The company had revenue of $984.40 million for the quarter, compared to the consensus estimate of $960.22 million. Hologic had a return on equity of 19.02% and a net margin of 11.99%. The company’s quarterly revenue was down 1.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.95 earnings per share. Equities analysts forecast that Hologic, Inc. will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In other Hologic news, Director Scott T. Garrett sold 10,000 shares of Hologic stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $79.72, for a total transaction of $797,200.00. Following the sale, the director now directly owns 57,039 shares of the company’s stock, valued at $4,547,149.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.66% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.